Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW 13,670
+290 (2.17%)
At close: Dec 5, 2025
Prestige BioPharma Cash Flow Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2019 |
| Net Income | 15,757 | 22,297 | -32,921 | 17,569 | -211,450 | -7,391 | Upgrade
|
| Depreciation & Amortization | 21,801 | 21,801 | 16,267 | 11,650 | 3,867 | 1,667 | Upgrade
|
| Loss (Gain) From Sale of Assets | 6.7 | 6.7 | -89.4 | -55.17 | -266.37 | 0.36 | Upgrade
|
| Asset Writedown & Restructuring Costs | -59,462 | -59,462 | - | 15,114 | 72,607 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | 693.39 | 18,966 | -15,081 | Upgrade
|
| Stock-Based Compensation | 470.11 | 470.11 | 52.41 | 1,943 | 3,774 | 2,955 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | -33.31 | -70,640 | - | - | Upgrade
|
| Other Operating Activities | -17,547 | -31,684 | -42,356 | -17,826 | 85,640 | 330.51 | Upgrade
|
| Change in Accounts Receivable | -228.75 | -228.75 | 674.94 | -1,050 | - | - | Upgrade
|
| Change in Inventory | -4,764 | -4,764 | 7,752 | -10,038 | -24,041 | - | Upgrade
|
| Change in Accounts Payable | 4,196 | 4,196 | 2,459 | -316.4 | 1,641 | - | Upgrade
|
| Change in Unearned Revenue | -310.36 | -310.36 | -5.21 | -660.52 | 564.62 | 578.1 | Upgrade
|
| Change in Other Net Operating Assets | -4,456 | -4,456 | 172.41 | -6,658 | 2,791 | 1,495 | Upgrade
|
| Operating Cash Flow | -44,538 | -52,135 | -48,027 | -60,274 | -45,907 | -15,446 | Upgrade
|
| Capital Expenditures | -30,670 | -40,742 | -20,063 | -48,363 | -56,429 | -949.11 | Upgrade
|
| Sale of Property, Plant & Equipment | 158.95 | 94.2 | 51.21 | 1,133 | 26,428 | - | Upgrade
|
| Divestitures | - | - | - | 40,039 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -5,826 | -6,028 | -7,463 | -17,254 | -11,684 | -17,162 | Upgrade
|
| Investment in Securities | -12,121 | -53,291 | 159,987 | -133,827 | -25,239 | - | Upgrade
|
| Other Investing Activities | -2,015 | -1,840 | -46.85 | 9,662 | 12,555 | -2,801 | Upgrade
|
| Investing Cash Flow | -50,474 | -101,806 | 132,465 | -148,610 | -184,685 | -20,912 | Upgrade
|
| Long-Term Debt Issued | - | 53,319 | - | 55,772 | - | 2,769 | Upgrade
|
| Long-Term Debt Repaid | - | -5,474 | -2,771 | -2,589 | -4,504 | -895.88 | Upgrade
|
| Net Debt Issued (Repaid) | 6,231 | 47,846 | -2,771 | 53,183 | -4,504 | 1,873 | Upgrade
|
| Issuance of Common Stock | 1,117 | 1,117 | 1,307 | - | - | 466,094 | Upgrade
|
| Other Financing Activities | 901.41 | 901.41 | - | - | - | -13,450 | Upgrade
|
| Financing Cash Flow | 8,250 | 49,864 | -1,464 | 53,183 | -4,504 | 454,517 | Upgrade
|
| Foreign Exchange Rate Adjustments | 364.07 | 1,850 | 608.72 | 6,888 | -3,177 | -277.54 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | -0 | 0 | 0 | 0 | Upgrade
|
| Net Cash Flow | -86,398 | -102,228 | 83,582 | -148,813 | -238,273 | 417,880 | Upgrade
|
| Free Cash Flow | -75,208 | -92,877 | -68,091 | -108,636 | -102,336 | -16,396 | Upgrade
|
| Free Cash Flow Margin | -521.86% | -648.33% | -9881.47% | -67125.45% | - | - | Upgrade
|
| Free Cash Flow Per Share | -1252.31 | -1542.04 | -1135.49 | -1807.71 | -1702.88 | -317.73 | Upgrade
|
| Cash Interest Paid | 3,317 | 10,742 | 6,082 | 1,834 | 436.07 | 477.47 | Upgrade
|
| Cash Income Tax Paid | - | -37.32 | -179.73 | 796.41 | 591.82 | 34.08 | Upgrade
|
| Levered Free Cash Flow | -138,354 | -122,563 | -46,364 | -23,046 | -114,523 | -22,341 | Upgrade
|
| Unlevered Free Cash Flow | -133,587 | -117,797 | -41,736 | -22,451 | -114,511 | -22,337 | Upgrade
|
| Change in Working Capital | -5,563 | -5,563 | 11,053 | -18,723 | -19,044 | 2,073 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.